Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B-cell lymphoma patients than the widely used International Prognostic Index. By identifying patients who are more likely to have poor outcomes early, the PET biomarker can contribute to the individualization of therapies, according to a study published in The Journal of Nuclear Medicine.
This article was originally published on MedicalXpress.com
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
In this article, we will introduce you to 12 incredibly effective foot massage techniques that will leave you feeling rejuvenated and relaxed. Foot massages aren’t just a luxury; they provide numerous health benefits, such as […]
© 2025 SimplyWell.ca